高密度脂蛋白抗炎能力与心脏及血管手术后急性肾损伤:一项前瞻性观察性研究
这项前瞻性观察性研究在四级医疗中心纳入100例长期服用他汀、接受择期心脏及血管手术的慢性肾脏病成人,于麻醉诱导时采集载脂蛋白B去除血清,与肿瘤坏死因子α刺激的人内皮细胞共孵育,以逆转录聚合酶链反应测定ICAM-1信使RNA评估HDL抗炎能力。结果显示HDL浓度与HDL抑制ICAM-1的能力不相关(Spearman R=0.05;p=0.64),12例(12%)存在促炎性HDL。促炎性HDL患者术后急性肾损伤发生率高于抗炎性HDL患者(p=0.046);校正急性肾损伤危险因素后,术前HDL抑制内皮ICAM-1能力越高,急性肾损伤风险越低(比值比0.88;95%CI 0.80-0.98;p=0.016),且独立于HDL浓度(p=0.018)。较高的长期他汀剂量与较高的HDL抑制内皮ICAM-1能力相关(p=0.045)。
要点
- 在100例长期服用他汀、接受择期心脏及血管手术的慢性肾脏病患者中,12例(12%)存在促炎性HDL,其术后急性肾损伤发生率高于抗炎性HDL患者(p=0.046)。
- 校正急性肾损伤危险因素后,术前HDL抑制内皮ICAM-1能力越高,术后急性肾损伤风险越低(比值比0.88;95%CI 0.80-0.98;p=0.016)。
- HDL抗炎能力与术后急性肾损伤的关联独立于HDL浓度(p=0.018);HDL浓度与HDL抑制ICAM-1能力不相关(Spearman R=0.05;p=0.64)。
- 较高的长期他汀剂量与较高的HDL抑制内皮ICAM-1能力相关(p=0.045)。
适用人群与场景
- 100例长期服用他汀、接受择期心脏及血管手术的慢性肾脏病成人,于四级医疗中心纳入。
诊断标准与关键阈值
- 于麻醉诱导时采集载脂蛋白B去除血清,与肿瘤坏死因子α刺激的人内皮细胞共孵育,以逆转录聚合酶链反应测定ICAM-1信使RNA评估HDL抗炎能力。
- 以酶联免疫吸附试验测定载脂蛋白A-I及患者血浆术后可溶性ICAM-1浓度。
- 12例(12%)存在促炎性HDL(功能失调)。
研究设计与关键结果
- 前瞻性观察性研究,纳入100例长期服用他汀、接受择期心脏及血管手术的慢性肾脏病成人,未设干预。
- HDL浓度与HDL抑制ICAM-1能力不相关(Spearman R=0.05;p=0.64)。
- 12例(12%)存在促炎性HDL;促炎性HDL患者术后急性肾损伤发生率高于抗炎性HDL患者(p=0.046)。
- 校正急性肾损伤危险因素后,术前HDL抑制内皮ICAM-1能力越高,急性肾损伤风险越低(比值比0.88;95%CI 0.80-0.98;p=0.016)。
- HDL抗炎能力与术后急性肾损伤的关联独立于HDL浓度(p=0.018)。
- 较高的长期他汀剂量与较高的HDL抑制内皮ICAM-1能力相关(p=0.045)。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,接受心脏及血管手术的慢性肾脏病患者中,存在功能失调的促炎性HDL者术后急性肾损伤风险较高;相反,HDL抗炎能力越高,术后急性肾损伤风险越低,且独立于HDL浓度。
- 作者认为,较高的长期他汀剂量与较高的HDL抗炎能力相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Acute kidney injury (AKI) predicts death after cardiac and vascular surgery. Higher preoperative high-density lipoprotein (HDL) concentrations are associated with less postoperative AKI. In animals, HDL's anti-inflammatory capacity to suppress endothelial cell adhesion molecule expression reduces kidney damage due to ischemia and hemorrhagic shock. The objective of this study is to evaluate the statistical relationship between HDL anti-inflammatory capacity and AKI after major cardiac and vascular surgery.
DESIGN: Prospective observational study.
SETTING: Quaternary medical center.
PATIENTS: One hundred adults with chronic kidney disease on long-term statin therapy undergoing major elective cardiac and vascular surgery.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Apolipoprotein B-depleted serum collected at anesthetic induction was incubated with tumor necrosis factor alpha stimulated human endothelial cells. Reverse transcriptase-polymerase chain reaction was used to measure intercellular adhesion molecule-1 (ICAM-1) messenger RNA. Enzyme-linked immunosorbent assay assays were used to measure apolipoprotein A-I and postoperative soluble ICAM-1 concentrations in patient plasma. HDL concentration did not correlate with HDL ICAM-1 suppression capacity (Spearman R = 0.05; p = 0.64). Twelve patients (12%) were found to have dysfunctional, pro-inflammatory HDL. Patients with pro-inflammatory HDL had a higher rate of postoperative AKI than patients with anti-inflammatory HDL ( p = 0.046). After adjustment for AKI risk factors, a higher preoperative HDL capacity to suppress endothelial ICAM-1 was independently associated with lower odds of AKI (odds ratio, 0.88; 95% CI, 0.80-0.98; p = 0.016). The association between HDL anti-inflammatory capacity and postoperative AKI was independent of HDL concentration ( p = 0.018). Further, a higher long-term statin dose was associated with higher HDL capacity to suppress endothelial ICAM-1 ( p = 0.045).
CONCLUSIONS: Patients with chronic kidney disease undergoing cardiac and vascular surgery who have dysfunctional, pro-inflammatory HDL have a higher risk of postoperative AKI compared with patients with anti-inflammatory HDL. Conversely, a higher HDL anti-inflammatory capacity is associated with a lower risk of postoperative AKI, independent of HDL concentration. Higher long-term statin dose is associated with higher HDL anti-inflammatory capacity.
参考来源
- Perkins ZM, Smith DK, Yancey PG, et al. High-Density Lipoprotein Anti-Inflammatory Capacity and Acute Kidney Injury After Cardiac and Vascular Surgery: A Prospective Observational Study. Crit Care Med. 2024. PMID: 39404489. doi:10.1097/CCM.0000000000006440
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。